Triple-negative breast cancer: challenges and opportunities of a heteroge ,
, Effect of bi-daily subcutaneous administration of 0.5 mg/kg homoharringtonine over 7 days on MDA-MB-468 xenografts in mice. A and B: Tumor volumes, absolute values. C: Tumor volume before and after treatment, mean ± SD. D and E: Mouse weight
,
, Am J Cancer Res, vol.9, issue.5, pp.1043-1060, 2019.
, Nat Rev Clin Oncol, vol.13, pp.674-690, 2016.
Rare breast cancer subtypes: histological, molecular, and clinical peculiarities, Oncologist, vol.19, pp.805-813, 2014. ,
Alarming burden of triple-negative breast cancer in India, Clin Breast Cancer, vol.18, pp.393-399, 2018. ,
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies, ESMO Open, vol.3, p.357, 2018. ,
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol, vol.26, pp.1275-1281, 2008. ,
Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies, Asia Pac J Clin Oncol, vol.14, pp.32-39, 2018. ,
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design, Clin Breast Cancer, vol.9, pp.29-33, 2009. ,
S. food and drug administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia, Oncologist, vol.19, pp.94-99, 2014. ,
Homoharringtonine and omacetaxine for myeloid hematological malignancies, J Hematol Oncol, vol.7, issue.2, 2014. ,
Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells, Sci Rep, vol.5, p.8477, 2015. ,
Homoharringtonine induced immune alteration for an efficient anti-tumor response in mouse models of non-small cell lung adenocarcinoma expressing Kras mutation, Sci Rep, vol.8, p.8216, 2018. ,
Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation, FEBS Lett, vol.257, pp.254-256, 1989. ,
Targeting the translation machinery in cancer, Nat Rev Drug Discov, vol.14, pp.261-278, 2015. ,
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia, Clin Cancer Res, vol.20, pp.1735-1740, 2014. ,
Translational dysregulation in cancer: molecular insights and potential clinical applications in biomarker development, Front Oncol, vol.7, p.158, 2017. ,
Cross-talk between protein synthesis, energy metabolism and autophagy in cancer, Curr Opin Genet Dev, vol.48, pp.104-111, 2018. ,
Control of cell migration through mRNA localization and local translation, Wiley Interdiscip Rev RNA, vol.6, pp.1-15, 2015. ,
The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy, Cell Death Differ, vol.18, pp.1414-1424, 2011. ,
Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis, Proc Natl Acad Sci U S A, vol.111, pp.261-266, 2014. ,
MCL-1 is a prognostic indicator and drug target in breast cancer, Cell Death Dis, vol.9, p.19, 2018. ,
Myeloid cell leukemia-1 is an important apoptotic survival factor in triplenegative breast cancer, Cell Death Differ, vol.22, pp.2098-2106, 2015. ,
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets, Cancer Discov, vol.4, pp.232-245, 2014. ,
Predictive biomarker profiling of > 6000 breast cancer patients shows heterogeneity in TNBC, with treatment implications, Clin Breast Cancer, vol.15, pp.473-481, 2015. ,
Unique biology of Mcl-1: therapeutic opportunities in cancer, Curr Mol Med, vol.8, pp.138-147, 2008. ,
Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation, J Biol Chem, vol.287, pp.10224-10235, 2012. ,
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models, Nature, vol.538, pp.477-482, 2016. ,
Mcl-1 inhibitors: a patent review, Expert Opin Ther Pat, vol.27, pp.163-178, 2017. ,
Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells, Mol Cancer Ther, vol.5, pp.723-731, 2006. ,
Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin, Int J Hematol, vol.87, pp.507-515, 2008. ,
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia, Blood, vol.117, pp.156-164, 2011. ,
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, vol.121, pp.2750-2767, 2011. ,
Establishment and characterisation of a new tumorigenic cell line with a normal karyotype derived from a human breast adenocarcinoma, Br J Cancer, vol.62, pp.8-13, 1990. ,
Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTENwild-type triple-negative breast cancer cells ,
, Mol Carcinog, vol.56, pp.1383-1394, 2017.
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol Rev, vol.58, pp.621-681, 2006. ,
A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia, Br J Cancer, vol.95, pp.253-259, 2006. ,
Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members, FEBS J, vol.283, pp.2661-2675, 2016. ,
cmyc oncogene protein synthesis is independent of the cell cycle in human and avian cells, Nature, vol.314, pp.366-369, 1985. ,
Fesik SW and Arteaga CL. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation, Cell Metab, vol.26, p.637, 2017. ,
A clinical trial of homoharringtonine in the treatment of advanced breast cancer, Tumori, vol.72, pp.395-398, 1986. ,
Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas, Cancer Treat Rep, vol.70, pp.375-379, 1986. ,
Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling, Biomed Pharmacother, vol.103, pp.435-442, 2018. ,
Induction of apoptosis by harringtonine and homoharri, Am J Cancer Res, vol.9, issue.5, pp.1043-1060, 2019. ,
, Yao Xue Xue Bao, vol.29, pp.667-672, 1994.
Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP), Am J Hematol, vol.76, pp.199-204, 2004. ,
Investigation into omacetaxine solution stability for in vitro study, Biomed Chromatogr, vol.26, pp.545-547, 2012. ,
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors, Cancer Chemother Pharmacol, vol.71, pp.35-41, 2013. ,
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer, Sci Transl Med, vol.9, 2017. ,
Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells, Leukemia, vol.25, pp.985-994, 2011. ,
PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells, Exp Biol Med (Maywood), vol.242, pp.996-1004, 2017. ,
Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells, PLoS One, vol.12, p.183578, 2017. ,